Compare WMS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMS | JAZZ |
|---|---|---|
| Founded | 1966 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 10.4B |
| IPO Year | 2014 | 2007 |
| Metric | WMS | JAZZ |
|---|---|---|
| Price | $149.90 | $197.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $181.25 | ★ $216.92 |
| AVG Volume (30 Days) | ★ 817.7K | 698.8K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.02 | N/A |
| Revenue | ★ $2,904,245,000.00 | $1,618,693,000.00 |
| Revenue This Year | $5.23 | $6.13 |
| Revenue Next Year | $12.79 | $7.75 |
| P/E Ratio | $29.39 | ★ N/A |
| Revenue Growth | ★ 1.04 | N/A |
| 52 Week Low | $100.50 | $98.59 |
| 52 Week High | $179.32 | $198.00 |
| Indicator | WMS | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 58.07 | 68.16 |
| Support Level | $143.91 | $159.78 |
| Resistance Level | $154.10 | $198.00 |
| Average True Range (ATR) | 5.15 | 4.72 |
| MACD | 2.39 | 0.85 |
| Stochastic Oscillator | 88.21 | 86.48 |
Advanced Drainage Systems Inc is the manufacturer of water management solutions in the stormwater and onsite septic wastewater industries, providing superior drainage solutions for use in the construction and agriculture marketplaces. Its products are used across a broad range of end markets and applications, including residential, non-residential, infrastructure and agriculture applications. It operates business in three distinct reportable segments: Pipe; International, and Infiltrator. It generates a greater proportion of revenue from its Pipe segment, which consists of Pipe product sales in the United States. The Infiltrator is a provider of plastic leachfield chambers and systems, septic tanks and accessories, for use in residential applications.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.